Introduction

Immunophenotyping
Immunoglobulin heavy chain (IgH) gene rearrangement in B cell malignancies has been analyzed initially by Southern blot Mononuclear cells were isolated from BM or PB by Ficollhybridization (SB). [1] [2] [3] [4] [5] However, since this approach requires a Paque sedimentation. Immunophenotyping was carried out by large amount of high molecular weight DNA from fresh flow cytometry using antibodies as follows: CD13, CD14, samples, it is not well suited to retrospective assessment of B CD33, and CD34 (myeloid markers); CD2, CD3, CD4, CD5, cell clonality. Recently several reports have advocated polyand CD7 (T cell markers); and CD10, CD19, CD20, and CD22 merase chain reaction (PCR) as a rapid technique for detection (B cell markers). A marker was positive when expressed by of IgH gene rearrangement (IgH-PCR). [6] [7] [8] [9] [10] [11] [12] Results from the two Ͼ20% of leukemic cells. techniques were similar. 13 Figure 1a ). DNA samples were taken from case 5 at the time of initial diagnosis, at complete remission (CR), and at relapse. Clonal IgH rearrangement Results was found at initial diagnosis and relapse, but not at CR (Figure 1b) .
The characteristics, immunophenotypes, IgH-PCR status, and therapeutic responses of the 35 patients are shown in Table 1 .
Cytogenetic analysis Immunophenotype
Cytogenetic studies on bone marrow samples from 33 patients were performed using standard Giemsa-trypsin banding All patients had myeloid markers on their leukemic cells. Five patients (14%) also expressed at least one B cell marker procedures. 20 ( Table 1) .
Clinical data and statistical analysis IgH-PCR analysis
Duration of survival was measured from the date of diagnosis. Duration of CR was measured from the date of achievement Clonal IgH gene rearrangement was detected in the blasts from 14 patients (40%) ( 
Response and survival analysis
Twenty-nine of 35 patients (83%) achieved CR ( Table 1 ). The CR rates were 100% for B cell marker-positive vs 80% for B cell antigen-negative patients (P = 0.85). Three patients (cases 10, 13 and 19) underwent BMT in first CR. As for IgH, 64% of IgH-PCR-positive patients attained CR, compared with 95% of IgH-PCR-negative patients (P = 0.02). Overall survival percentages for IgH-PCR positive and negative patients at 25 months were 29 and 88%, respectively ( Figure 3 ). The prognosis of IgH-PCR-negative patients was significantly better than IgH-PCRpositive patients (P = 0.02). The CR rates excluding FAB M3 were 67% for IgH-PCR-positive patients and 94% for IgH-PCRnegative patients. Overall survival of IgH-PCR positive and negative patients at 25 months excluding FAB M3 were 26 and 85%, respectively. There was no significant difference in response rate or survival between FAB non-M3 patients who were randomized into the two groups for induction therapy. antigen-negative AML. Previous reports have noted IgH gene 
Discussion
M, male; F, female; BM, bone marrow; PB, peripheral blood; P, positive; N, negative; +, clonal rearrangement; −, no clonal rearrangement; CR, complete remission; NR, no response.
Figure 2
Polyacrylamide gel analysis of IgH-PCR products from seven patients (cases 8, 9, 10, 11, 12, 13 and 14). Clonal IgH gene rearrangement was detected in two patients (cases 8 and 14). rearrangement in two of 14 cases of childhood AML, 15 and positive case by SB. 22 Our study, performed retrospectively using PCR, disclosed relatively more cases with rearrangement than past studies, possibly because of the greater sensitivity of CR rate of IgH-PCR-negative AML (95% CR rate) is significantly higher, and survival somewhat better, than the rates for IgH-PCR (PCR, 0.01-0.05%; SB, 5% 19 ). Lymphoid marker-positive AML may have a poor response PCR-positive AML (64% CR rate). Two of seven patients with AML M3 which has a good prognosis, had IgH rearrangement. to therapy.
23-25 Expression of CD7 in the absence of other lymphoid antigens is a particularly poor prognostic factor for However analysis excluding the patients with FAB M3 still showed that IgH-PCR-negative patients had a better prognosis. AML. 25 There has been no consideration of IgH gene rearrangement in AML as a prognostic marker. In the present study, the IgH-PCR positivity may be a poor prognostic factor in AML. patients with AML using PCR, detecting clonal rearrangement 
